Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

CNBC’s Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results. Make some room on ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

According to the Cleveland Clinic, anabolic steroids are drugs made in a lab that mimic the effects of the male sex hormone, ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

How Can Low-Dose Ketamine, a 'Lifesaving' Drug for Major Depression, Alleviate Symptoms Within Hours? Nov. 18, 2024 — Neuroscientists have identified the binding site of low-dose ketamine ...

Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond to traditional medications.